Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
-
J Gynecol Oncol. 2017 Mar;28(2):e32. English. Review. https://doi.org/10.3802/jgo.2017.28.e32
Yamagami W , Nagase S , Takahashi F , Ino K , Hachisuga T , Aoki D , Katabuchi H .
Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan. gami@z8.keio.jp
Department of Obstetrics and Gynecology, Yamagata University School of Medicine, Yamagata, Japan.
Department of Clinical Research Network, Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan.
Department of Obstetrics and Gynecology, Wakayama Medical University, Wakayama, Japan.
Department of Obstetrics and Gynecology, University of Occupational and Environmental Health Japan, Kitakyushu, Japan.
Department of Obstetrics and Gynecology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Gynecologic Tumor Committee, Japan Society of Obstetrics and Gynecology, Tokyo, Japan.
Abstract

Cervical, endometrial, and ovarian cancers, have both high morbidity and mortality among the gynecologic malignant tumors in Japan. The present study was conducted using both the population-based cancer registry and the gynecologic cancer registry to elucidate the characteristics of gynecologic malignant tumors in Japan. Based on nationwide estimates from the population-based cancer registry in Japan, the morbidities and mortality of cervical, endometrial, and ovarian cancers were obtained and used for analysis. Clinicopathologic factors for cervical cancer, endometrial cancer, ovarian cancer, including age, clinical stage, postsurgical stage, histological type, therapeutic strategy, and prognosis were retrieved from the gynecologic cancer registry published by the Japan Society of Obstetrics and Gynecology and used for analysis. The morbidities of cervical, endometrial, and ovarian cancers were 10,908, 13,606, and 9,384 women in 2012, respectively. The prevalence of endometrial cancer has significantly and consistently been increasing and represents the most common gynecologic malignant tumor in Japan. The mortalities of cervical, endometrial, and ovarian cancers were 2.1, 1.3, and 3.2 per 100,000 in 2012, respectively. In 2014, 52.2% of cervical cancer patients were classified as stage I, 22.5% as stage II, 10.2% as stage III, and 11.2% as stage IV. In addition, 71.9% of endometrial cancer patients were classified as stage I, 6.0% as stage II, 13.3% as stage III, and 7.5% as stage IV. Finally, 43.2% of ovarian cancer patients were classified as stage I, 9.1% as stage II, 27.6% as stage III, and 7.2% as stage IV. Twelve point five percent of ovarian cancer patients received neoadjuvant chemotherapy.

Copyright © 2019. Korean Association of Medical Journal Editors.